Dopaminergic-based pharmacotherapies for depression

European Neuropsychopharmacology

Volumn 16, Issue 6, 2006, Pages 391-402

  Papakostas, George I ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Depression; Dopamine; Treatment

Indexed keywords

AMANTADINE; AMFEBUTAMONE; AMINEPTINE; ANTIDEPRESSANT AGENT; BROFAROMINE; BROMOCRIPTINE MESILATE; CATECHOLAMINE O METHYLTRANSFERASE INHIBITOR; DEXAMPHETAMINE; DOPAMINE RECEPTOR AFFECTING AGENT; DOPAMINE UPTAKE INHIBITOR; ENTACAPONE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; IPRONIAZID; ISOCARBOXAZID; METHYLPHENIDATE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NOMIFENSINE MALEATE; PAROXETINE; PEMOLINE; PERGOLIDE MESILATE; PHENELZINE; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TOLCAPONE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY DISORDER; BODY WEIGHT DISORDER; CENTRAL NERVOUS SYSTEM; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COGNITIVE DEFECT; DIARRHEA; DOPAMINE METABOLISM; DOPAMINE UPTAKE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG DEPENDENCE; DRUG FEVER; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; FATIGUE; FIBROMYALGIA; GASTROINTESTINAL TOXICITY; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSIVE CRISIS; LIVER TOXICITY; MAJOR DEPRESSION; META ANALYSIS; MONOAMINE METABOLISM; NAUSEA; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NEUROPHYSIOLOGY; NONHUMAN; NORADRENERGIC ACTIVITY; OBESITY; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; REVIEW; SEIZURE; SEROTONERGIC ACTIVITY; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SYSTEMATIC REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; DOPAMINE AGENTS; HUMANS;

EID: 33745676287     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2005.12.002     Document Type: Review

References (185)

1. Allard P., and Norlen M. Unchanged density of caudate nucleus dopamine uptake sites in depressed suicide victims. J. Neural Transm. 104 11-12 (1997) 1353-1360
2. Allard P., and Norlen M. Caudate nucleus dopamine D(2) receptors in depressed suicide victims. Neuropsychobiology 44 2 (2001) 70-73
3. Alevizos B., Christodoulou G.N., Ioannidis C., Voulgari A., Mantidis A., and Spiliadis C. The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome. Clin. Neuropharmacol. 12 Suppl 2 (1989) S66-S76
4. Anderson J.W., Greenway F.L., Fujioka K., Gadde K.M., McKenney J., and O'Neil P.M. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes. Res. 10 7 (2002) 633-641
5. Appolinario J.C., Godoy-Matos A., Fontenelle L.F., Carraro L., Cabral M., Vieira A., and Coutinho W. An open-label trial of sibutramine in obese patients with binge-eating disorder. J. Clin. Psychiatry 63 1 (2002) 28-30
6. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., Golden R.N., Martin P., Potter W.Z., and Richelson E. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56 9 (1995) 395-401
7. Askinazi C., Weintraub R.J., and Karamouz N. Elderly depressed females as a possible subgroup of patients responsive to methylphenidate. J. Clin. Psychiatry 47 9 (1986) 467-469
8. Baker G.B., and Prior T.I. Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs. Ann. Med. 34 7-8 (2002) 537-543
9. Baker G.B., Urichuk L.J., McKenna K.F., and Kennedy S.H. Metabolism of monoamine oxidase inhibitors. Cell. Mol. Neurobiol. 19 3 (1999) 411-426
10. Bergquist J., Traskman-Bendz L., Lindstrom M.B., and Ekman R. Suicide-attempters having immunoglobulin G with affinity for dopamine in cerebrospinal fluid. Eur. Neuropsychopharmacol. 12 2 (2002) 153-158
11. Bodkin J.A., Lasser R.A., Wines Jr. J.D., Gardner D.M., and Baldessarini R.J. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J. Clin. Psychiatry 58 4 (1997) 137-145
12. Bondarev M.L., Bondareva T.S., Young R., and Glennon R.A. Behavioral and biochemical investigations of bupropion metabolites. Eur. J. Pharmacol. 474 1 (2003) 85-93
13. Boral G.C., and Shah L.P. The beneficial effects of amineptine (Survector 100) in the treatment of depression: preliminary results of an Indian multicenter trial. Clin. Neuropharmacol. 12 Suppl 2 (1989) S51-S57
14. Bornstein S. Cross-over trial comparing the antidepressant effects of amineptine and maprotiline. Curr. Med. Res. Opin. 6 2 (1979) 107-110
15. Bouckoms A., and Mangini L. Pergolide: an antidepressant adjuvant for mood disorders?. Psychopharmacol. Bull. 29 2 (1993) 207-211
16. Bouras N., and Bridges P. Bromocriptine in depression. Curr. Med. Res. Opin. 8 (1982) 150-153
17. Bowden C., Cheetham S.C., Lowther S., Katona C.L., Crompton M.R., and Horton R.W. Dopamine uptake sites, labelled with [3H]GBR12935, in brain samples from depressed suicides and controls. Eur. Neuropsychopharmacol. 7 4 (1997) 247-252
18. Boyer P., Lecrubier Y., Stalla-Bourdillon A., and Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 39 1 (1999) 25-32
19. Breitbart W., Rosenfeld B., Kaim M., and Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch. Intern. Med. 161 3 (2001) 411-420
20. Bremner J.D., Abrahams L.M., Crupie J.E., McCawley A., Proctor R.C., and Sathananthan G.L. Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients. J. Clin. Psychiatry 45 4 Pt 2 (1984) 56-59
21. Brunswick D.J., Amsterdam J.D., Mozley P.D., and Newberg A. Greater availability of brain dopamine transporters in major depression shown by [99 m Tc]TRODAT-1 SPECT imaging. Am. J. Psychiatry 160 10 (2003) 1836-1841
22. Cantini F., Bellandi F., Niccoli L., and Di Munno O. Fluoxetine associated with cyclobenzaprine in the treatment of primary fibromyalgia. Minerva Med. 85 (1994) 97-100
23. Cardenas L., Houle S., Kapur S., and Busto U.E. Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET. Synapse 51 1 (2004) 27-31
24. Clayton A.H., Pradko J.F., Croft H.A., Montano C.B., Leadbetter R.A., Bolden-Watson C., Bass K.I., Donahue R.M., Jamerson B.D., and Metz A. Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry 63 4 (2002) 357-366
25. Clayton A.H., Warnock J.K., Kornstein S.G., Pinkerton R., Sheldon-Keller A., and McGarvey E.L. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J. Clin. Psychiatry 65 1 (2004) 62-67
26. Cohn J.B., Varga L., and Lyford A. A two-center double-blind study of nomifensine, imipramine, and placebo in depressed geriatric outpatients. J. Clin. Psychiatry 45 4 Pt 2 (1984) 68-72
27. Coleman C.C., Cunningham L.A., Foster V.J., Batey S.R., Donahue R.M., Houser T.L., and Ascher J.A. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann. Clin. Psychiatry 11 4 (1999) 205-215
28. Coleman C.C., King B.R., Bolden-Watson C., Book M.J., Segraves R.T., Richard N., Ascher J., Batey S., Jamerson B., and Metz A. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin. Ther. 23 7 (2001) 1040-1058
29. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., and Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11 2 (2000) 58-65
30. Crane G.E. The psychiatric side-effects of iproniazid. Am. J. Psychiatry 112 (1956) 494-501
31. Croft H., Settle Jr. E., Houser T., Batey S.R., Donahue R.M., and Ascher J.A. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin. Ther. 21 4 (1999) 643-658
32. Croft H., Houser T.L., Jamerson B.D., Leadbetter R., Bolden-Watson C., Donahue R., and Metz A. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin. Ther. 24 4 (2002) 662-672
33. Dalery J., Rochat C., Peyron E., and Bernard G. The efficacy and acceptability of amineptine versus fluoxetine in major depression. Int. Clin. Psychopharmacol. 12 Suppl 3 (1997) S35-S38
34. DeBattista C., Solvason H.B., Poirier J., Kendrick E., and Schatzberg A.F. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J. Clin. Psychopharmacol. 23 1 (2003) 27-30
35. D'Haenen H.A., and Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol. Psychiatry 35 2 (1994) 128-132
36. Dong J., and Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl.) 155 1 (2001) 52-57
37. Dunner D.L., Zisook S., Billow A.A., Batey S.R., Johnston J.A., and Ascher J.A. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J. Clin. Psychiatry 59 7 (1998) 366-373
38. Ebert D., Feistel H., Loew T., and Pirner A. Dopamine and depression-striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl.) 126 1 (1996) 91-94
39. El-Mallakh R.S. An open study of methylphenidate in bipolar depression. Bipolar Disord. 2 1 (2000) 56-59
40. Engstrom G., Alling C., Blennow K., Regnell G., and Traskman-Bendz L. Reduced cerebrospinal HVA concentrations and HVA / 5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur. Neuropsychopharmacol. 9 5 (1999) 399-405
41. Fabre L.F., Brodie H.K., Garver D., and Zung W.W. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J. Clin. Psychiatry 44 5 Pt 2 (1983) 88-94
42. Fann W.E., Lyle F.A., and Higginbotham W. Nomifensine vs. imipramine in depressed inpatients. J. Clin. Psychiatry 45 4 Pt 2 (1984) 60-62
43. Fava M., and Kaji J. Continuation and maintenance treatments of major depressive disorder. Psychol. Annals 42 (1994) 281-290
44. Fava M., and Rosenbaum J.F. Pharmacotherapy and somatic therapies. In: Beckham E.E., and Leber W.R. (Eds). Handbook of Depression (1995), Guilford Publications, New York 280-301
45. Fava M., Rosenbaum J.F., Kolsky A.R., Alpert J.E., Nierenberg A.A., Spillmann M., Moore C., Renshaw P., Bottiglieri T., Moroz G., and Magni G. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J. Clin. Psychopharmacol. 19 4 (1999) 329-335
46. Fava M., Papakostas G.I., Petersen T., Mahal Y., Quitkin F., Stewart J., and McGrath P. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann. Clin. Psychiatry 15 1 (2003) 17-22
47. Fava M., Rush A.J., Thase M.E., Clayton A., Stahl S.M., Pradko J.F., and Johnston J.A. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim care companion. J. Clin. Psychiatry 7 3 (2005) 106-113
48. Fawcett J., Kravitz H.M., Zajecka J.M., and Schaff M.R. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J. Clin. Psychopharmacol. 11 2 (1991) 127-132
49. Feighner J.P., Herbstein J., and Damlouji N. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J. Clin. Psychiatry 46 6 (1985) 206-209
50. Feighner J.P., Gardner E.A., Johnston J.A., Batey S.R., Khayrallah M.A., Ascher J.A., and Lineberry C.G. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J. Clin. Psychiatry 52 8 (1991) 329-335
51. Ferguson J., Cunningham L., Merideth C., Apter J., Feighner J., Ionescu-Pioggia M., Samara B., Johnston J.A., and Ascher J. Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder. Ann. Clin. Psychiatry 6 3 (1994) 153-160
52. Fernandez F., Levy J.K., Samley H.R., Pirozzolo F.J., Lachar D., Crowley J., Adams S., Ross B., and Ruiz P. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int. J. Psychiatry Med. 25 1 (1995) 53-67
53. Foley K.F., and Cozzi N.V. Inhibition of transport function and desipramine binding at the human noradrenaline transporter by N-ethylmaleimide and protection by substrate analogs. Naunyn Schmiedeberg's Arch. Pharmacol. 365 6 (2002) 457-461
54. Fowler J.S., Volkow N.D., Logan J., Franceschi D., Wang G.J., MacGregor R., Shea C., Garza V., Pappas N., Carter P., Netusil N., Bridge P., Liederman D., Elkashef A., Rotrosen J., and Hitzemann R. Evidence that l-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. Life Sci. 68 24 (2001) 2759-2768
55. Fryer J.D., and Lukas R.J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. 288 1 (1999) 88-92
56. Gadde K.M., Parker C.B., Maner L.G., Wagner II H.R., Logue E.J., Drezner M.K., and Krishnan K.R. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes. Res. 9 9 (2001) 544-551
57. Garattini S. Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: a review. Int. Clin. Psychopharmacol. 12 Suppl 3 (1997) S15-S19
58. Garattini S., and Mennini T. Pharmacology of amineptine: synthesis and updating. Clin. Neuropharmacol. 12 Suppl 2 (1989) S13-S18
59. Gerlach M., Double K., Arzberger T., Leblhuber F., Tatschner T., and Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J. Neural Transm. 110 10 (2003) 1119-1127
60. Giers G., Salama A., and Mueller-Eckhardt C. Follow-up study on 24 patients with nomifensine-induced immune haemolytic anaemia. Transfus. Med. 1 2 (1991) 115-119
61. Glick S.D., Haskew R.E., Maisonneuve I.M., Carlson J.N., and Jerussi T.P. Enantioselective behavioral effects of sibutramine metabolites. Eur. J. Pharmacol. 397 1 (2000) 93-102
62. Goldberg J.F., Burdick K.E., and Endick C.J. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am. J. Psychiatry 161 3 (2004) 564-566
63. Goldenberg D., Mayskiy M., Mossey C., Ruthazer R., and Schmid C. A randomized, double-blind, crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthitis Rheum. 39 (1996) 1852-1859
64. Goldstein B.J., Brauzer B., Kentsmith D., Rosenthalm S., and Charalampous K.D. Double-blind placebo-controlled multicenter evaluation of the efficacy and safety of nomifensine in depressed outpatients. J. Clin. Psychiatry 45 4 Pt 2 (1984) 52-55
65. Goodnick P.J., Sandoval R., Brickman A., and Klimas N.G. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol. Psychiatry 32 9 (1992) 834-838
66. Granier F., Girard M., Schmitt L., Boscredon J., Oules J., and Escande M. Depression and anxiety: mianserin and nomifensine compared in a double-blind multicentre trial. Acta Psychiatr. Scand., Suppl. 320 (1985) 67-74
67. Green T.R. Bupropion for SSRI-induced fatigue. J. Clin. Psychiatry 58 4 (1997) 174
68. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
69. Hamner M.B., and Diamond B.I. Plasma dopamine and norepinephrine correlations with psychomotor retardation, anxiety, and depression in non-psychotic depressed patients: a pilot study. Psychiatry Res. 64 3 (1996) 209-211
70. Hannonen P., Malminiemi K., Yli-Kerttula U., Isomeri R., and Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br. J. Rheumatol. 37 (1998) 1279-1286
71. Healy E., and McKeon P. Dopaminergic sensitivity and prediction of antidepressant response. J. Psychopharmacol. 14 2 (2000) 152-156
72. Hickie I.B., Wilson A.J., Wright J.M., Bennett B.K., Wakefield D., and Lloyd A.R. A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. J. Clin. Psychiatry 61 9 (2000) 643-648
73. Inoue T., Tsuchiya K., Miura J., Sakakibara S., Denda K., Kasahara T., and Koyama T. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol. Psychiatry 40 2 (1996) 151-153
74. Izumi T., Inoue T., Kitagawa N., Nishi N., Shimanaka S., Takahashi Y., Kusumi I., Odagaki Y., Denda K., Ohmori T., and Koyama T. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J. Affect Disord. 61 1-2 (2000) 127-132
75. Jain A.K., Kaplan R.A., Gadde K.M., Wadden T.A., Allison D.B., Brewer E.R., Leadbetter R.A., Richard N., Haight B., Jamerson B.D., Buaron K.S., and Metz A. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes. Res. 10 10 (2002) 1049-1056
76. Jansen W., and Siegfried K. Nomifensine in geriatric inpatients: a placebo-controlled study. J. Clin. Psychiatry 45 4 Pt 2 (1984) 63-67
77. Kaufmann M.W., Cassem N.H., Murray G.B., and Jenike M. Use of psychostimulants in medically ill patients with neurological disease and major depression. Can. J. Psychiatry 29 1 (1984) 46-49
78. Kavoussi R.J., Segraves R.T., Hughes A.R., Ascher J.A., and Johnston J.A. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J. Clin. Psychiatry 58 12 (1997) 532-537
79. Kennedy S.H., McCann S.M., Masellis M., McIntyre R.S., Raskin J., McKay G., and Baker G.B. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J. Clin. Psychiatry 63 3 (2002) 181-186
80. Kennedy S.H., Fulton K., Rafi-Tari S., Green A., Cohen N.L., Bagby M.R., in press. Differences in sexual dysfunction between men and women with depression: a comparison before and after treatment with bupropion and paroxetine. Can J Psychiatry.
81. Kinney J.L. Nomifensine maleate: a new second-generation antidepressant. Clin. Pharm. 4 6 (1985) 625-636
82. Klimek V., Schenck J.E., Han H., Stockmeier C.A., and Ordway G.A. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol. Psychiatry 52 7 (2002) 740-748
83. Klimke A., Larisch R., Janz A., Vosberg H., Muller-Gartner H.W., and Gaebel W. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res. 90 2 (1999) 91-101
84. Kuhn R. The treatment of depressive states with G22355 (imipramine hydrochloride). Am. J. Psychiatry 115 (1958) 459-464
85. Laasonen-Balk T., Kuikka J., Viinamaki H., Husso-Saastamoinen M., Lehtonen J., and Tiihonen J. Striatal dopamine transporter density in major depression. Psychopharmacology (Berl.) 144 3 (1999) 282-285
86. Lam R.W., Hossie H., Solomons K., and Yatham L.N. Citalopram and bupropion-SR combining versus switching in patients with treatment-resistant depression. J. Clin. Psychiatry 65 3 (2004) 337-340
87. Lambert G., Johansson M., Agren H., and Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch. Gen. Psychiatry 57 (2000) 787-793
88. Lattanzi L., Dell'Osso L., Cassano P., Pini S., Rucci P., Houck P.R., Gemignani A., Battistini G., Bassi A., Abelli M., and Cassano G.B. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 4 5 (2002) 307-314
89. Lavretsky H., and Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am. J. Geriatr. Psychiatry 9 3 (2001) 298-303
90. Lavretsky H., Kim M.D., Kumar A., and Reynolds III C.F. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J. Clin. Psychiatry 64 12 (2003) 1410-1414
91. Lazarus L.W., Winemiller D.R., Lingam V.R., Neyman I., Hartman C., Abassian M., Kartan U., Groves L., and Fawcett J. Efficacy and side effects of methylphenidate for poststroke depression. J. Clin. Psychiatry 53 12 (1992) 447-449
92. Lazarus L.W., Moberg P.J., Langsley P.R., and Lingam V.R. Methylphenidate and nortriptyline in the treatment of poststroke depression: a retrospective comparison. Arch. Phys. Med. Rehabil. 75 4 (1994) 403-406
93. Learned-Coughlin S.M., Bergstrom M., Savitcheva I., Ascher J., Schmith V.D., and Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol. Psychiatry 54 8 (2003) 800-505
94. Lemoine P., Achaintre A., Balvay G., Bonnet H., Burgat R., Carrier C., and Perrin J. Double-blind trial of amineptine and clomipramine in the treatment of depression. Curr. Med. Res. Opin. 7 4 (1981) 234-240
95. Levant B., and Bancroft G.N. Inhibition of [3H]quinpirole binding by a monoamine oxidase inhibitor in subcellular fractions of rat striatum. Life Sci. 63 18 (1998) 1643-1651
96. Levant B., Moehlenkamp J.D., Morgan K.A., Leonard N.L., and Cheng C.C. Modulation of [3H]quinpirole binding in brain by monoamine oxidase inhibitors: evidence for a potential novel binding site. J. Pharmacol. Exp. Ther. 278 1 (1996) 145-153
97. Levin A. Nomifensine and maprotiline in endogenous depression: comparative efficacy and side effects. Int. Pharmacopsychiatry 17 Suppl 1 (1982) 89-96
98. Li S.X., Perry K.W., and Wong D.T. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42 2 (2002) 181-190
99. Lingam V.R., Lazarus L.W., Groves L., and Oh S.H. Methylphenidate in treating poststroke depression. J. Clin. Psychiatry 49 4 (1988) 151-153
100. Little K.Y. d-Amphetamine versus methylphenidate effects in depressed inpatients. J. Clin. Psychiatry 54 9 (1933) 349-355
101. Longborn P.D., Glaudin V., and Painter J.R. Pramipexole in the treatment of markedly depressed outpatients. 39th New Clinical Drug Evaluation Unit Annual Meeting (1999)
102. Lopez-Ibor Alino J.J., Ayuso Gutierez J.L., Montejo Iglesias M.L., and Ramons J.L. A double-blind clinical comparison between nomifensine and amitriptyline in the treatment of endogenous depressions. Int. Pharmacopsychiatry 17 Suppl 1 (1982) 97-105
103. Macher J.P., and Mirabaud C. A double-blind comparison of moclobemide and amineptine in the treatment of depressed out-patients. Psychopharmacology (Berl.) 106 Suppl (1992) S116-S117
104. Maggio R., Scarselli M., Novi F., Millan M.J., and Corsini G.U. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J. Neurochem. 87 3 (2003) 631-641
105. Masand P., Murray G.B., and Pickett P. Psychostimulants in post-stroke depression. J. Neuropsychiatry Clin. Neurosci. 3 1 (1991) 23-27
106. Masand P., Pickett P., and Murray G.B. Psychostimulants for secondary depression in medical illness. Psychosomatics 32 2 (1991) 203-208
107. Masand P.S., Anand V.S., and Tanquary J.F. Psychostimulant augmentation of second generation antidepressants: a case series. Depress Anxiety 7 2 (1998) 89-91
108. McGrath P.J., Stewart J.W., Harrison W., and Quitkin F.M. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol. Bull. 23 1 (1987) 169-172
109. McGrath P.J., Stewart J.W., Nunes E.V., Ocepek-Welikson K., Rabkin J.G., Quitkin F.M., and Klein D.F. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am. J. Psychiatry 150 1 (1993) 118-123
110. Mendis N., Hanwella D.R., Weerasinghe C., Illesinghe D.S., and De Silva D.A. Double-blind comparative study: amineptine (Survector 100) versus imipramine. Clin. Neuropharmacol. 12 Suppl 2 (1989) S58-S65
111. Mercuri N.B., Calabresi P., and Bernardi G. The electrophysiological actions of dopamine and dopaminergic drugs on neurons of the substantia nigra pars compacta and ventral tegmental area. Life Sci. 51 10 (1992) 711-718
112. Meyer J.H., Kruger S., Wilson A.A., Christensen B.K., Goulding V.S., Schaffer A., Minifie C., Houle S., Hussey D., and Kennedy S.H. Lower dopamine transporter binding potential in striatum during depression. NeuroReport 12 18 (2001) 4121-4125
113. Meyer J.H., Goulding V.S., Wilson A.A., Hussey D., Christensen B.K., and Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl.) 163 1 (2002) 102-105
114. Michelson D., Bancroft J., Targum S., Kim Y., and Tepner R. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am. J. Psychiatry 157 2 (2000) 239-243
115. Miller D.K., Sumithran S.P., and Dwoskin L.P. Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. J. Pharmacol. Exp. Ther. 302 3 (2002) 1113-1122
116. Modell J.G., Katholi C.R., Modell J.D., and DePalma R.L. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin. Pharmacol. Ther. 61 4 (1997) 476-487
117. Montejo A.L., Llorca G., Izquierdo J.A., and Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish working group for the study of psychotropic-related sexual dysfunction. J. Clin. Psychiatry 62 Suppl 3 (2001) 10-21
118. Natelson B.H., Cheu J., Pareja J., Ellis S.P., Policastro T., and Findley T.W. Randomized, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. Psychopharmacology (Berl.) 124 3 (1996) 226-230
119. Natelson B.H., Cheu J., Hill N., Bergen M., Korn L., Denny T., and Dahl K. Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. Neuropsychobiology 37 3 (1998) 150-154
120. Neumeister A., Willeit M., Praschak-Rieder N., Asenbaum S., Stastny J., Hilger E., Pirker W., Konstantinidis A., and Kasper S. Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol. Med. 31 8 (2001) 1467-1473
121. Neusch C., Schnierle S., and Moser A. Selegiline induces dopamine release through ATP-sensitive potassium channels in the rat caudate-putamen in vitro. Neurochem. Int. 31 2 (1997) 307-311
122. Nierenberg A.A., Keefe B.R., Leslie V.C., Alpert J.E., Pava J.A., Worthington III J.J., Rosenbaum J.F., and Fava M. Residual symptoms in depressed patients who respond acutely to fluoxetine. J. Clin. Psychiatry 60 4 (1999) 221-225
123. Nomikos G.G., Damsma G., Wenkstern D., and Fibiger H.C. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 2 4 (1989) 273-279
124. Nordin C., Siwers B., and Bertilsson L. Bromocriptine treatment of depressive disorders. Clinical and biochemical effects. Acta Psychiatr. Scand. 64 1 (1981) 25-33
125. Norregaard J., Volkmann H., and Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 61 (1995) 445-449
126. Olin J., and Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 37 1 (1996) 57-62
127. Ong S.B., and Lee C.T. A double-blind comparison of nomifensine and amitriptyline in the treatment of depression. Acta Psychiatr. Scand. 63 3 (1981) 198-207
128. Paes de Sousa M., and Tropa J. Evaluation of the efficacy of amineptine in a population of 1,229 depressed patients: results of a multicenter study carried out by 135 general practitioners. Clin. Neuropharmacol. 12 Suppl 2 (1989) S77-S86
129. Papakostas G.I., and Fava M. Monoamine-based pharmacotherapy. Biology of Depression, First Edition. Edited by Licino (2005), J. Wiley-VCH Verlag GmbH, Weinheim, Germany
130. Papakostas G.I., Petersen T., Denninger J.W., Tossani E., Pava J.A., Alpert J.E., Nierenberg A.A., and Fava M. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin. Psychopharmacol. 24 5 (2004) 507-511
131. Papakostas G.I., Nutt D.J., Tucker V.L., Krishen A.X., and Fava M. Resolution of fatigue and sleepiness during the treatment of MDD with Bupropion and the SSRIs. American College of Neuropsychopharmacology Anuual Meeting (2005)
132. Parsey R.V., Oquendo M.A., Zea-Ponce Y., Rodenhiser J., Kegeles L.S., Pratap M., Cooper T.B., Van Heertum R., Mann J.J., and Laruelle M. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol. Psychiatry 50 5 (2001) 313-322 (Sep 1)
133. Peeters M., Maloteaux J.M., and Hermans E. Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum. Neurosci. Lett. 343 3 (2003) 205-209
134. Perugi G., Toni C., Ruffolo G., Frare F., and Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 34 4 (2001) 137-141
135. Petersen T., Dording C., Neault N.B., Kornbluh R., Alpert J.E., Nierenberg A.A., Rosenbaum J.F., and Fava M. A survey of prescribing practices in the treatment of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 26 1 (2002) 177-187
136. Petersen T., Papakostas G.I., Posternak M.A., Kant A., Guyker W.M., Iosifescu D.V., Yeung A.S., Nierenberg A.A., and Fava M. Empirical testing of two models for staging antidepressant treatment resistance. J. Clin. Psychopharmacol. 25 4 (2005) 336-341
137. Pickett P., Masand P., and Murray G.B. Psychostimulant treatment of geriatric depressive disorders secondary to medical illness. J. Geriatr. Psychiatry Neurol. 3 3 (1990) 146-151
138. Piercey M.F. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin. Neuropharmacol. 21 3 (1998) 141-151
139. Poldinger W., and Streichenwein S.M. A clinical trial comparing nomifensine and nortriptyline. Int. Pharmacopsychiatry 17 Suppl 1 (1982) 106-115
140. Post R.M., Gerner R.H., Carman J.S., Gillin J.C., Jimerson D.C., Goodwin F.K., and Bunney Jr. W.E. Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response. Arch. Gen. Psychiatry 35 5 (1978) 609-615
141. Rampello L., Nicoletti G., and Raffaele R. Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses. Acta Psychiatr. Scand. 84 6 (1991) 552-554
142. Rampello L., Nicoletti G., Raffaele R., and Drago F. Comparative effects of amitriptyline and amineptine in patients affected by anxious depression. Neuropsychobiology 31 3 (1995) 130-134
143. Reimherr F.W., Cunningham L.A., Batey S.R., Johnston J.A., and Ascher J.A. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clin. Ther. 20 3 (1998) 505-516
144. Rogóz Z., Kubera M., Basta-Kaim A., Lason W., Dudek D., Wróbel A., and Zieba A. Effect of combined treatment with imipramine and amantadine in patients with drug-resistant unipolar depression - clinical and immunological studies citation. Eur. Neuropsychopharmacol. 13 4 (2003) S207
145. Rothenhausler H.B., Ehrentraut S., von Degenfeld G., Weis M., Tichy M., Kilger E., Stoll C., Schelling G., and Kapfhammer H.P. Treatment of depression with methylphenidate in patients difficult to wean from mechanical ventilation in the intensive care unit. J. Clin. Psychiatry 61 10 (2000) 750-755
146. Roy A., Pickar D., Linnoila M., and Potter W.Z. Plasma norepinephrine level in affective disorders. Relationship to melancholia. Arch. Gen. Psychiatry 42 12 (1995) 1181-1185
147. Roy A., De Jong J., and Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study. Arch. Gen. Psychiatry 46 7 (1989) 609-612
148. Roy A., Lamparski D., De Jong J., Adinoff B., Ravitz B., George D.T., Nutt D., and Linnoila M. Cerebrospinal fluid monoamine metabolites in alcoholic patients who attempt suicide. Acta Psychiatr. Scand. 81 1 (1990) 58-61
149. Roy A., Karoum F., and Pollack S. Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch. Gen. Psychiatry. 49 6 (1992) 447-450
150. Rush A.J., Batey S.R., Donahue R.M., Ascher J.A., Carmody T.J., and Metz A. Does pretreatment anxiety predict response to either bupropion SR or sertraline?. J. Affect Disord. 64 1 (2001) 81-87
151. Rush A.J., Schmid R., Haight B., Zisook S., Rockett C., and Carmody T. Does pretreatment anxiety or insomnia predict acute response to bupropion SR?. Eur. Neuropsychopharmacol. 13 4 (2003) S253
152. Saunders C., Ferrer J.V., Shi L., Chen J., Merrill G., Lamb M.E., Leeb-Lundberg L.M., Carvelli L., Javitch J.A., and Galli A. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl. Acad. Sci. U. S. A. 97 12 (2000) 6850-6855
153. Scarzella L., Scarzella R., Mailland F., and Bergamasco B. Amineptine in the management of the depressive syndromes. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 9 4 (1985) 429-439
154. Schiwy W., Heath W.R., and Delini-Stula A. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients. J. Neural Transm., Suppl. 28 (1989) 33-44
155. Segraves R.T., Kavoussi R., Hughes A.R., Batey S.R., Johnston J.A., Donahue R., and Ascher J.A. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. J. Clin. Psychopharmacol. 20 2 (2000) 122-128
156. Segraves R.T., Horrigan J.P., Wightman D.S., Modell J.G., Richard N.E., Krishen A., and Tucker V.L. Comparative antidepressant efficacy of bupropion and escitalopram. Eur. Neuropsychopharmacol. 15 s3 (2005) 453
157. Settle E.C., Stahl S.M., Batey S.R., Johnston J.A., and Ascher J.A. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin. Ther. 21 3 (1999) 454-463
158. Shah P.J., Ogilvie A.D., Goodwin G.M., and Ebmeier K.P. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol. Med. 27 6 (1997) 1247-1256
159. Slawson M.H., Taccogno J.L., Foltz R.L., and Moody D.E. Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. J. Anal. Toxicol. 26 7 (2002) 430-437
160. Slemmer J.E., Martin B.R., and Damaj M.I. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 295 1 (2000) 321-327
161. Spier S.A. Use of bupropion with SRIs and venlafaxine. Depress Anxiety 7 2 (1998) 73-75
162. Sporn J., Ghaemi S.N., Sambur M.R., Rankin M.A., Recht J., Sachs G.S., Rosenbaum J.F., and Fava M. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann. Clin. Psychiatry 12 3 (2000) 137-140
163. Stern W.C., Harto-Truax N., and Bauer N. Efficacy of bupropion in tricyclic-resistant or intolerant patients. J. Clin. Psychiatry 44 5 Pt 2 (1983) 148-152
164. Stoll A.L., Pillay S.S., Diamond L., Workum S.B., and Cole J.O. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J. Clin. Psychiatry 57 2 (1996) 72-76
165. Stryjer R., Strous R.D., Shaked G., Bar F., Feldman B., Kotler M., Polak L., Rosenzcwaig S., and Weizman A. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int. Clin. Psychopharmacol. 18 2 (2003) 93-96
166. Szabo Z., Argyelan M., Kanyo B., Juhasz A., Kovacs Z.S., Pavics L., and Janka Z. The effects of bupropion on the activity of dopamine transporter in depression - preliminary results. Eur. Neuropsychopharmacol. 13 4 (2003) S210
167. Thase M.E., Frank E., Mallinger A.G., Hamer T., and Kupfer D.J. Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. J. Clin. Psychiatry 53 1 (1992) 5-11
168. Thase M.E., Trivedi M.H., and Rush A.J. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 12 3 (1995) 185-219
169. Thase M.E., Haight B.R., Richard N., Rockett C.B., Mitton M., Modell J.G., Vanmeter S., Harriett A.E., and Wang Y. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J. Clin. Psychiatry 66 8 (2005) 974-981
170. Theohar C., Fischer-Cornelssen K., Brosch H., Fischer E., and Petrovic D. A comparative, multicenter trial between bromocriptine and amitriptyline in the treatment of endogenous depression. Arzneimittelforschung 32 (1982) 783-787
171. Trivedi M.H., Rush A.J., Carmody T.J., Donahue R.M., Bolden-Watson C., Houser T.L., and Metz A. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?. J. Clin. Psychiatry 62 10 (2001) 776-781
172. Van Amerongen P. Double-blind clinical trial of the antidepressant action of amineptine. Curr. Med. Res. Opin. 6 2 (1979) 93-100
173. Vauterin C., and Bazot M.A. Double-blind controlled trial of amineptine versus trimipramine in depression. Curr. Med. Res. Opin. 6 2 (1979) 101-106
174. Verbeeck W.J., Berk M., Paiker J., and Jersky B. The prolactin response to sulpiride in major depression: the role of the D2 receptor in depression. Eur. Neuropsychopharmacol. 11 3 (2001) 215-220
175. Vercoulen J.H., Swanink C.M., and Zitman F.G. Randomized double-blind placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 347 9005 (1996) 858-861
176. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., and Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry. 155 10 (1998) 1325-1331
177. Volkow N.D., Fowler J.S., Wang G., Ding Y., and Gatley S.J. Mechanism of action of methylphenidate: insights from PET imaging studies. J. Atten. Disord. 6 Suppl 1 (2002) S31-S43
178. Waehrens J., and Gerlach J. Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients. J. Affect. Disord. 3 2 (1981) 193-202
179. Wagner G.J., and Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 61 6 (2000) 436-440
180. Weihs K.L., Settle Jr. E.C., Batey S.R., Houser T.L., Donahue R.M., and Ascher J.A. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J. Clin. Psychiatry 61 3 (2000) 196-202
181. White P.D., and Cleary K.J. An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome. Int. Clin. Psychopharmacol. 12 1 (1997) 47-52
182. Wistedt B., Agren H., Bjaring B., Kallstrom B., Lund M., Mansby J., Peterson L.E., and Roos B.E. Nomifensine and amitriptyline in the treatment of depression. A multi-centre double-blind comparison. Acta Psychiatr. Scand. 68 3 (1983) 212-220
183. Wolfe F., Cathey M.A., and Hawley D.J. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand. J. Rheumatol. 23 (1994) 255-259
184. Woods S.W., Tesar G.E., Murray G.B., and Cassem N.H. Psychostimulant treatment of depressive disorders secondary to medical illness. J. Clin. Psychiatry. 47 1 (1986) 12-15
185. Zarate C.A., Payne J.L., Singh J., Quiroz J.A., Luckenbaugh D.A., Denicoff K.D., Charney D.S., and Manji H. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry 56 1 (2004) 54-60